Researchers at the Center for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh reported in the May 19, 2021, issue of Science Translational Medicine that the Bcl2/w/xL targeting senolytic compound, ABT-263 (navitoclax) could reverse the age-related fibrosis characteristic of and improve kidney function.
Aging, which is associated with various pathologies such atherosclerosis and cancer, is characterized by an accumulation of senescent cells. Cellular senescence blocks cell proliferation, but it decreases the health of the old by littering tissues with dysfunctional senescent cells.
